How much cognitive therapy, for which patients, will prevent depressive relapse?

Area of Science:

• Psychiatry
• Clinical Psychology
• Translational Science

Background:

• Deciding when to discontinue successful cognitive therapy for recurrent major depressive disorder (MDD) remains unclear.
• Existing research highlights the probability of relapse after pharmacotherapy cessation but lacks similar clarity for cognitive therapy.
• Translational tools are developed to bridge the gap between research findings and clinical practice for MDD treatment decisions.

Purpose of the Study:

• To develop practical tools for patients, clinicians, and administrators to inform decisions about continuing or stopping cognitive therapy.
• To facilitate evidence-based choices regarding continuation-phase cognitive therapy (C-CT) for responders to acute-phase cognitive therapy (A-CT) with recurrent MDD.

Main Methods:

• Utilized data from a randomized clinical trial comparing C-CT with assessment-only for A-CT responders.
• Analyzed findings on residual symptoms after A-CT and their association with relapse/recurrence over 2 years.
• Developed tools based on scores from six readily available measures of depressive symptom severity.

Main Results:

• Continuation-phase cognitive therapy (C-CT) reduced relapse over 8 months compared to assessment-only for A-CT responders.
• Higher residual symptoms after A-CT predicted a greater need for C-CT to prevent relapse/recurrence over 2 years.
• Provided specific scores and associated relapse/recurrence probabilities for residual symptoms at 8, 12, and 24 months.

Conclusions:

• The developed tools can assist individual patients and providers in making informed decisions about continuing or discontinuing cognitive therapy.
• These tools aim to improve treatment adherence and outcomes for patients with recurrent major depressive disorder.
• Results are specific to a 20-session A-CT trial by experienced therapists and require further replication.